Czerw T, et al. - Researchers, in this retrospective study, determined the impact of anti-thymocyte globulin (ATG) on allogeneic peripheral blood stem cell transplantation (allo-PBSCT) outcomes for adults with Philadelphia-negative acute lymphoblastic leukemia (Ph-neg ALL). Survival free from relapse, grade 3 to 4 acute graft-versus-host disease (aGVHD), and chronic graft-versus-host disease (cGVHD ie, graft-versus-host disease–free/relapse-free survival [GRFS]) were assessed. Improved GRFS was achieved with the use of ATG in patients with Ph-neg ALL treated with allo-PBSCT. Furthermore, it was noted to be related to a reduced risk of both grade 2 to 4 and grade 3 to 4 aGVHD. Overall, its use may be considered in this setting.